Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Opioid-Related Disorders | 6 | 2024 | 35 | 3.960 |
Why?
|
Analgesics, Opioid | 11 | 2024 | 74 | 3.640 |
Why?
|
Buprenorphine | 3 | 2024 | 8 | 1.760 |
Why?
|
Benzodiazepines | 2 | 2023 | 13 | 1.610 |
Why?
|
Drug Overdose | 2 | 2022 | 6 | 1.530 |
Why?
|
Humans | 26 | 2024 | 5357 | 1.380 |
Why?
|
Health Services Accessibility | 3 | 2024 | 27 | 1.340 |
Why?
|
Opiate Substitution Treatment | 2 | 2024 | 9 | 1.170 |
Why?
|
Pharmacists | 3 | 2023 | 41 | 1.050 |
Why?
|
Motivation | 2 | 2023 | 69 | 0.990 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 275 | 0.990 |
Why?
|
Texas | 7 | 2024 | 185 | 0.990 |
Why?
|
Methadone | 1 | 2024 | 2 | 0.970 |
Why?
|
Focus Groups | 1 | 2024 | 15 | 0.960 |
Why?
|
Physicians | 1 | 2023 | 17 | 0.890 |
Why?
|
Fear | 1 | 2023 | 8 | 0.870 |
Why?
|
Community Pharmacy Services | 1 | 2023 | 8 | 0.860 |
Why?
|
Prescription Drug Misuse | 1 | 2023 | 9 | 0.850 |
Why?
|
Self Efficacy | 1 | 2023 | 34 | 0.850 |
Why?
|
Students, Pharmacy | 2 | 2021 | 73 | 0.850 |
Why?
|
Adult | 12 | 2024 | 1651 | 0.810 |
Why?
|
Alcoholism | 1 | 2023 | 43 | 0.810 |
Why?
|
Chronic Pain | 1 | 2022 | 23 | 0.800 |
Why?
|
Pandemics | 3 | 2024 | 82 | 0.780 |
Why?
|
Practice Patterns, Physicians' | 2 | 2024 | 47 | 0.730 |
Why?
|
Preceptorship | 1 | 2020 | 4 | 0.720 |
Why?
|
Social Desirability | 1 | 2020 | 4 | 0.720 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 8 | 0.710 |
Why?
|
Coronavirus Infections | 1 | 2020 | 8 | 0.710 |
Why?
|
Melanoma | 3 | 2024 | 26 | 0.680 |
Why?
|
Health Expenditures | 3 | 2024 | 19 | 0.630 |
Why?
|
Education, Pharmacy | 1 | 2020 | 73 | 0.630 |
Why?
|
Narcotic Antagonists | 3 | 2024 | 10 | 0.630 |
Why?
|
Prescriptions | 3 | 2023 | 19 | 0.580 |
Why?
|
United States | 7 | 2024 | 505 | 0.580 |
Why?
|
Young Adult | 7 | 2024 | 837 | 0.530 |
Why?
|
Middle Aged | 7 | 2024 | 1068 | 0.510 |
Why?
|
Female | 9 | 2024 | 2752 | 0.500 |
Why?
|
Multiple Sclerosis | 3 | 2021 | 46 | 0.500 |
Why?
|
Qualitative Research | 2 | 2024 | 44 | 0.450 |
Why?
|
Male | 6 | 2024 | 2704 | 0.430 |
Why?
|
Naloxone | 2 | 2022 | 3 | 0.390 |
Why?
|
Adolescent | 6 | 2024 | 800 | 0.350 |
Why?
|
Treatment Outcome | 4 | 2024 | 208 | 0.340 |
Why?
|
Aged | 5 | 2024 | 822 | 0.320 |
Why?
|
Breast Neoplasms | 2 | 2020 | 104 | 0.310 |
Why?
|
Cohort Studies | 3 | 2023 | 128 | 0.300 |
Why?
|
Immunotherapy | 2 | 2024 | 22 | 0.290 |
Why?
|
Drug Prescriptions | 3 | 2024 | 26 | 0.280 |
Why?
|
Retrospective Studies | 6 | 2024 | 382 | 0.260 |
Why?
|
Skin Neoplasms | 1 | 2024 | 12 | 0.240 |
Why?
|
Social Determinants of Health | 1 | 2024 | 10 | 0.230 |
Why?
|
Interrupted Time Series Analysis | 2 | 2024 | 12 | 0.230 |
Why?
|
Emergency Medical Services | 1 | 2024 | 4 | 0.230 |
Why?
|
Logistic Models | 1 | 2023 | 66 | 0.220 |
Why?
|
Help-Seeking Behavior | 1 | 2023 | 2 | 0.220 |
Why?
|
Health Care Surveys | 1 | 2023 | 14 | 0.220 |
Why?
|
Decision Trees | 1 | 2023 | 9 | 0.220 |
Why?
|
Point-of-Care Systems | 1 | 2023 | 18 | 0.220 |
Why?
|
Internet | 1 | 2023 | 32 | 0.210 |
Why?
|
Risk Assessment | 1 | 2023 | 49 | 0.210 |
Why?
|
Feasibility Studies | 1 | 2023 | 51 | 0.210 |
Why?
|
Self Report | 1 | 2023 | 72 | 0.210 |
Why?
|
Intention | 1 | 2022 | 18 | 0.210 |
Why?
|
Neoplasms | 1 | 2024 | 98 | 0.200 |
Why?
|
Reproducibility of Results | 1 | 2023 | 340 | 0.200 |
Why?
|
Drug Storage | 1 | 2021 | 2 | 0.200 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 51 | 0.190 |
Why?
|
Fingolimod Hydrochloride | 1 | 2021 | 9 | 0.190 |
Why?
|
Cancer Pain | 1 | 2020 | 3 | 0.190 |
Why?
|
Drug Utilization | 1 | 2020 | 5 | 0.180 |
Why?
|
Azithromycin | 1 | 2020 | 2 | 0.180 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 3 | 0.180 |
Why?
|
Betacoronavirus | 1 | 2020 | 7 | 0.180 |
Why?
|
Faculty, Pharmacy | 1 | 2020 | 11 | 0.180 |
Why?
|
Prescription Drug Monitoring Programs | 1 | 2020 | 7 | 0.180 |
Why?
|
Health Policy | 1 | 2020 | 7 | 0.180 |
Why?
|
Cost of Illness | 1 | 2020 | 6 | 0.180 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 20 | 0.170 |
Why?
|
Prescription Drugs | 1 | 2020 | 15 | 0.170 |
Why?
|
Surveys and Questionnaires | 1 | 2021 | 267 | 0.170 |
Why?
|
Pain, Postoperative | 2 | 2023 | 6 | 0.100 |
Why?
|
Risk Factors | 2 | 2024 | 183 | 0.100 |
Why?
|
Longitudinal Studies | 2 | 2021 | 144 | 0.090 |
Why?
|
Health Care Costs | 1 | 2024 | 11 | 0.060 |
Why?
|
Multimorbidity | 1 | 2024 | 4 | 0.060 |
Why?
|
Proportional Hazards Models | 1 | 2024 | 30 | 0.060 |
Why?
|
Registries | 1 | 2024 | 24 | 0.060 |
Why?
|
Insurance, Health | 1 | 2024 | 4 | 0.060 |
Why?
|
Anticonvulsants | 1 | 2024 | 6 | 0.060 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 10 | 0.060 |
Why?
|
Sex Factors | 1 | 2024 | 77 | 0.060 |
Why?
|
Antidepressive Agents | 1 | 2024 | 14 | 0.060 |
Why?
|
Pain Management | 1 | 2024 | 14 | 0.060 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2023 | 8 | 0.060 |
Why?
|
Thyroid Gland | 1 | 2023 | 3 | 0.050 |
Why?
|
Patient Discharge | 1 | 2023 | 17 | 0.050 |
Why?
|
Injections | 1 | 2021 | 10 | 0.050 |
Why?
|
Students | 1 | 2023 | 122 | 0.050 |
Why?
|
Administration, Oral | 1 | 2021 | 35 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 19 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2020 | 10 | 0.050 |
Why?
|
Anxiety | 1 | 2023 | 171 | 0.050 |
Why?
|
Models, Economic | 1 | 2020 | 3 | 0.040 |
Why?
|
Mastectomy | 1 | 2020 | 5 | 0.040 |
Why?
|
Child | 1 | 2024 | 649 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2020 | 17 | 0.040 |
Why?
|
Chronic Disease | 1 | 2020 | 26 | 0.040 |
Why?
|
Linear Models | 1 | 2020 | 60 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 38 | 0.040 |
Why?
|
Time Factors | 1 | 2020 | 176 | 0.040 |
Why?
|